Development and validation of a symptom-based activity index for adults with eosinophilic esophagitis

Alain M. Schoepfer*, Alex Straumann, Radoslaw Panczak, Michael Coslovsky, Claudia E. Kuehni, Elisabeth Maurer, Nadine A. Haas, Yvonne Romero, Ikuo Hirano, Jeffrey A. Alexander, Nirmala Gonsalves, Glenn T. Furuta, Evan S. Dellon, John Leung, Margaret H. Collins, Christian Bussmann, Peter Netzer, Sandeep K. Gupta, Seema S. Aceves, Mirna ChehadeFouad J. Moawad, Felicity T. Enders, Kathleen J. Yost, Tiffany H. Taft, Emily Kern, Marcel Zwahlen, Ekaterina Safroneeva, Sami R. Achem, Amindra S. Arora, Oral Alpan, David Armstrong, Stephen E. Attwood, Joseph H. Butterfield, Michael D. Crowell, Giovanni De Petris, Kenneth R. DeVault, Eric Drouin, Benjamin Enav, David E. Fleischer, Amy Foxx-Orenstein, Dawn L. Francis, Gordon H. Guyatt, Lucinda A. Harris, Amir F. Kagalwalla, David A. Katzka, Hirohito Kita, Murli Krishna, James J. Lee, John C. Lewis, Kaiser Lim

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

196 Scopus citations


BACKGROUND & AIMS: Standardized instruments are needed to assess the activity of eosinophilic esophagitis (EoE) and to provide end points for clinical trials and observational studies. We aimed to develop and validate a patient-reported outcome (PRO) instrument and score, based on items that could account for variations in patient assessments of disease severity. We also evaluated relationships between patient assessment of disease severity and EoE-associated endoscopic, histologic, and laboratory findings.

METHODS: We collected information from 186 patients with EoE in Switzerland and the United States (69.4% male; median age, 43 y) via surveys (n = 135), focus groups (n = 27), and semistructured interviews (n = 24). Items were generated for the instruments to assess biologic activity based on physician input. Linear regression was used to quantify the extent to which variations in patient-reported disease characteristics could account for variations in patient assessment of EoE severity. The PRO instrument was used prospectively in 153 adult patients with EoE (72.5% male; median age, 38 y), and validated in an independent group of 120 patients with EoE (60.8% male; median age, 40.5 y).

RESULTS: Seven PRO factors that are used to assess characteristics of dysphagia, behavioral adaptations to living with dysphagia, and pain while swallowing accounted for 67% of the variation in patient assessment of disease severity. Based on statistical consideration and patient input, a 7-day recall period was selected. Highly active EoE, based on endoscopic and histologic findings, was associated with an increase in patient-assessed disease severity. In the validation study, the mean difference between patient assessment of EoE severity (range, 0-10) and PRO score (range, 0-8.52) was 0.15.

CONCLUSIONS: We developed and validated an EoE scoring system based on 7 PRO items that assess symptoms over a 7-day recall period.

Original languageEnglish (US)
Pages (from-to)1255-1266.e21
Issue number6
StatePublished - Dec 1 2014


  • Disease Activity Measurement
  • Esophagus
  • Marker
  • Patient-Reported Outcome

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology


Dive into the research topics of 'Development and validation of a symptom-based activity index for adults with eosinophilic esophagitis'. Together they form a unique fingerprint.

Cite this